Association of Serum Interleukin-6 and Interleukin-8 Levels with Clinical Benefit from Immune Checkpoint Inhibitors in Patients with Advanced Gastric Cancer

Liang Han^1*, Yuan Yuan^1*, Yu Feng¹, Xiaowu Li¹

Show Less

¹ Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou, China

EJMO 2023, 7(3), 227–231; https://doi.org/10.14744/ejmo.2023.38141

Received: 2 August 2023 | Accepted: 28 August 2023 | Published online: 6 October 2023

© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )

Download PDF

Cite

XML

Abstract

Objectives: This study mainly analyzes the association between serum interleukin-6(IL-6) and interleukin-8(IL-8) levels and clinical benefit from immune checkpoint inhibitors in patients with advanced gastric cancer.

Methods: The clinical characteristics of 51 patients with advanced gastric cancer, diagnosed in our hospital and treated with immune checkpoint inhibitors, were analyzed retrospectively in our study.

Results: After three cycles of immunotherapy, the level of serum IL-6 decreased in 10 patients (37%) and the level of serum IL-8 decreased in 27 patients (52%). Compared with patients with increased serum IL-6 level, patients with decreased serum IL-6 level tended to have higher partial response (PR), stable disease (SD), but the difference was not statistically significant. Compared with patients with increased serum IL-8 level, there were significant differences in PR, SD for patients with decreased serum IL-8 level(P≤0.05). Patients with decreased serum IL-6 or IL-8 levels tended to have better progression-free survival(PFS) and overall survival(OS) than those with increased serum IL-6 or IL-8 levels.

Conclusion: The changes in IL-6 and IL-8 levels could be as predictive indicators to predict benefit from immune checkpoint inhibition in advanced gastric cancer. Patients with decreased serum IL-6 or IL-8 levels during immunotherapy may achieve better clinical benefit.

Keywords

Gastric cancer

interleukin-6

interleukin-8

immune checkpoint inhibitor

Conflict of interest

None declared.

References

1. Takei S, Kawazoe A, Shitara K. The New Era of Immunotherapy in Gastric Cancer. Cancers (Basel) 2022;14:1054.
2. Choi S, Park S, Kim H, et-al. Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches. Biomedicines 2022;10:543.
3. Hogner A, Moehler M. Immunotherapy in Gastric Cancer. Curr Oncol 2022;29:1559-1574.
4. Diaz L A, Jr., Le D T. PD-1 Blockade in Tumors with MismatchRepair Deficiency. N Engl J Med 2015;373:1979.
5. Suh Y S, Na D, Lee J S, et al. Comprehensive Molecular Characterization of Adenocarcinoma of the Gastroesophageal Junction Between Esophageal and Gastric Adenocarcinomas. Ann Surg 2022;275:706-717.
6. Yu H Y, Li C P, Huang Y H, et al. Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. Cancers (Basel) 2022;14: 218.
7. Lee K E, Khoi P N, Xia Y, et al. Helicobacter pylori and interleukin-8 in gastric cancer. World J Gastroenterol 2013;19:8192- 8202.
8. Keegan A, Ricciuti B, Garden P, et al. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer 2020;8 e000678.
9. Bilusic M, Heery C R, Collins J M, et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer 2019;7:240.
10. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
11. Chang X, Ge X, Zhang Y, et al. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore) 2022;101: e29304.
12. Wang F H, Zhang X T, Li Y F, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747-795.
13. Wu Y X, Zhou X Y, Wang J Q, et al. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer. Immunotherapy 2023;15:101-105.
14. Janjigian Y Y, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398:27-40.
15. Shen J, Wang Z. Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review. Front Oncol 2022;12:934249.
16. Hindson J. KEYNOTE-811: pembrolizumab in advanced HER2 (+) gastric cancer. Nat Rev Gastroenterol Hepatol 2022;19:79.

Previous article in this issue

Next article in this issue

Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing